TOKYO, May 1, 2026 /PRNewswire/ -- Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results